Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of May 2026, specifically dated May 12, 2026. The report details the execution of an "at-the-market" sales agreement to facilitate the potential future sale of ordinary shares.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new securities offering arrangement.
Material Changes
On May 12, 2026, the Company entered into a Sales Agreement with A.G.P./Alliance Global Partners (the Sales Agent). Key terms include:
- The Company may offer and sell ordinary shares from time to time through the Sales Agent.
- Sales will be conducted pursuant to the Company's effective Form F-3 registration statement (File No. 333-290046).
- The Company is not obligated to sell any shares under this agreement.
- The Sales Agent will be paid a commission of 3.0% of the aggregate gross proceeds from each sale.
- Net proceeds are intended for working capital and general corporate purposes.
Guidance, Outlook, and Risks
Management commentary is limited to the intent to use proceeds for working capital. The filing notes that the Sales Agent's obligations are subject to certain conditions and customary representations and warranties. No specific financial guidance, risk factors, or contingencies regarding operations are disclosed in this specific report.
Investor Verification Checklist
- Verify the current market price of Icecure Medical Ltd. ordinary shares to assess potential dilution impact.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific price, time, or size limits the Company may impose.
- Confirm the Company's current cash position and working capital needs to understand the urgency of potential sales.
- Check subsequent filings for actual share sales executed under this agreement.